Psoriasis, Topical, Imiquimod (IMQ)-Induced
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
Psoriasis is a chronic inflammatory skin disease characterized by focal formation of plaque psoriasis, erythema, skin thickening, epidermal alterations, and T cell and dendritic cell infiltration. Topical application of Imiquimod (IMQ) on the ear of mice induces skin inflammation, which closely resembles human plaque-type psoriasis. IMQ-induced psoriasis is commonly used to study the mechanisms of skin inflammation and evaluate the therapeutic efficacy.
ORGANISM
Mouse
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 6 male BALB/c mice at 8 weeks of age are used. Daily topical dose (TOP) of commercially available IMQ cream (5%) 15 mg on the right ear from Day 1 for 9 consecutive days. Vehicle, Dexamethasone, and test articles are administered by TOP once daily from Day 1 for 9 consecutive days (1 hr before IMQ challenge). Ear swelling is measured by an experimenter blinded as to treatment group, with a dial thickness micrometer gauge as an index of inflammation on Day 0, 2, 4, 6 and 8. On Day 10, ear swelling was measured 24 hr after the last dosing. The animals are sacrificed and then the ears are harvested and weighed. Ear edema is calculated by subtracting the thickness of Day 0 (normal control) from Day n (treated ear). Percent inhibition is calculated according to the formula: (Ic −It)/Ic x 100, where Ic and It refer to increase of ear thickness (mm) in control and treated mice, respectively. Additional analyses that can be requested include ear weight, biomarker analysis (protein and/or mRNA), cell populations by FACS, spleen weight and histopathology etc. Suggested Testing: n=6/group (study design dependent). Doses may be administered TOP, PO, IV, IP and SC.
CRITERIA FOR SIGNIFICANCE
p<0.05 compared to vehicle control is considered significant activity
TURNAROUND TIME
STANDARD
40 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Inflammation/Allergy
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences